Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease

Hicks, Caitlin W.; Pandya, Mayur; Itin, Ilia; Fernández, Hubert H.

doi:10.1016/j.parkreldis.2011.03.003

Cited by 36 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, GABA-acting drugs such as topiramate (Bermejo, 2008), zonisamide (Bermejo et al, 2010) and valproate were effective in reducing ICD (Hicks et al, 2011) and DDS (Sriram et al, 2013) in PD patients in small open-label studies. However, as valproate is known to promote choreiform movements in non-PD subjects (Silver and Factor, 2013;van de Velde et al, 2011), further investigation is required to validate its use for the treatment of ICD in PD patients.…”

Section: The Gabaergic Systemmentioning

confidence: 99%

“…Unknown: may inhibit GABA transaminase ICD in pilot studies (Hicks et al, 2011;Sriram et al, 2013) internet addiction (Przepiorka et al, 2014) Adenosine (Carpentier et al, 1996) Pharmacological approaches for the treatment of dyskinesia, impulsivity and addictions in animal models of PD, behavioral impulsivity and addictions.…”

Section: Impulsivity and Addictions In General Populationmentioning

confidence: 99%

See 1 more Smart Citation

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Jiménez-Urbieta

Gago

Riva

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Section: The Gabaergic Systemmentioning

confidence: 99%

Section: Impulsivity and Addictions In General Populationmentioning

confidence: 99%

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Jiménez-Urbieta

Gago

Riva

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…HDACis) have been studied for their potent neuroprotective effects in several Parkinsonian models. A promising example of such an HDAC inhibitor, VPA, has been studied most intensively (Kidd and Schneider, 2011) and the first cases of its utilization in relation to PD treatment have been reported recently (Hicks et al, 2011). Notably, not all neuroprotective effects of HDAC inhibition are due to deacetylation of chromatin-bound histones.…”

Section: Using Epigenetic Regulation To Promote Mdda Neuron Survivalmentioning

confidence: 99%

Epigenetic mechanisms in the development and maintenance of dopaminergic neurons

et al. 2013

View full text Add to dashboard Cite

SummaryMesodiencephalic dopaminergic (mdDA) neurons are located in the ventral mesodiencephalon and are involved in psychiatric disorders and severely affected in neurodegenerative diseases such as Parkinson's disease. mdDA neuronal development has received much attention in the last 15 years and many transcription factors involved in mdDA specification have been discovered. More recently however, the impact of epigenetic regulation has come into focus, and it's emerging that the processes of histone modification and DNA methylation form the basis of genetic switches that operate during mdDA development. Here, we review the epigenetic control of mdDA development, maturation and maintenance. As we highlight, epigenetic mechanisms play a pivotal role in all of these processes and the knowledge gathered from studying epigenetics in these contexts may aid our understanding of mdDA-related pathologies. Key words: Brain, Development, Dopamine, Epigenetics, Gene regulation, Midbrain IntroductionIf you turn this page, both the decision you make and the action that you carry out are significantly influenced by the amount of dopamine (DA; see Glossary, Box 1) released from dopaminergic neurons within your brain. Mesodiencephalic dopaminergic (mdDA) neurons located in the substantia nigra pars compacta (SNc; see Glossary, Box 1), in particular, are essential for motor functions whereas mdDA neurons of the ventral tegmental area (VTA; see Glossary, Box 1) and the retrorubal field (RRF; see Glossary, Box 1) are involved in the regulation of emotions and reward . Notably, severe loss of SNc mdDA neurons is a pathological hallmark of Parkinson's disease (PD) (Sulzer, 2007). By contrast, mdDA neurons in the VTA and RRF, which remain intact in PD, are part of the mesocorticolimbic system (see Glossary, Box 1), in which defective DA neurotransmission has been implicated in the development of drug addiction, depression and schizophrenia (Nestler, 2000). Given their involvement in neurodegenerative diseases and psychiatric disorders, mdDA neurons have been studied intensively in recent years.In the last two decades, a variety of molecular approaches have revealed factors that are specific for mdDA neuronal subsets or that guide their spatial organization ; recently, a pathway that molecularly distinguishes SNc DA neurons from those located in the VTA was identified (Jacobs et al., 2011). In addition to molecular profiling of DA neurons, however, a second level of complexity has been added by the rapidly emerging field of epigenetics, which has provided new insights into the origin and maintenance of distinctive gene expression patterns in mdDA neurons. Current definitions of epigenetics often emphasize the heritability of changes in gene expression throughout cell divisions that are not due to alterations in DNA sequence. However, perhaps a more appropriate definition of epigenetics, especially when applying this term to mature neurons that cannot divide, is postulated by Adrian Bird: 'The structural adaptation of chromosomal regio...

show abstract

“…VPA intake does not cause serious adverse reactions in ALS (Piepers et al, 2009) Rare frequency of P/CD in patients treated with VPA occurs after 1 year of treatment and at least 1 year of follow-up (Easterford et al, 2004). Effectively releases the ICDs of PD in 3 cases (Hicks et al, 2011) BDA-410 Calpain inhibitors; mTORindependent…”

Section: Latrepirdine Inhibits Mtorc1mentioning

confidence: 99%

Toward therapeutic targets for SCA3: Insight into the role of Machado–Joseph disease protein ataxin-3 in misfolded proteins clearance

Fischhaber

et al. 2015

Progress in Neurobiology

View full text Add to dashboard Cite

Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease

Cited by 36 publications

References 9 publications

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Epigenetic mechanisms in the development and maintenance of dopaminergic neurons

Toward therapeutic targets for SCA3: Insight into the role of Machado–Joseph disease protein ataxin-3 in misfolded proteins clearance

Contact Info

Product

Resources

About